Mechanism of action of the trastuzumab biosimilar CT-P6.

Related Articles

Mechanism of action of the trastuzumab biosimilar CT-P6.

Expert Opin Biol Ther. 2018 Dec 13;:1-11

Authors: Jeong SA, Choi JM, Park JM, Lee JY, Lee SJ, Lee SY, Lee SY, Park YA, Jeong HJ, Song YC, Kim SH, Chang SJ

Abstract
OBJECTIVES: Therapeutic monoclonal antibody biosimilars are expected to help reduce the sizeable economic burden of targeted treatments. Trastuzumab (Herceptin®), a recombinant humanized monoclonal antibody that binds to the extracellular domain of HER2, is approved for use in HER2-overexpressing breast cancer (in both the adjuvant and metastatic settings) and HER2-positive gastric cancer. CT-P6 (Herzuma®) is a biosimilar of trastuzumab, designed to bind with high affinity and specificity to the same HER2 epitope as the reference product. We investigated whether CT-P6 exerts its effects through the same mechanism of action as trastuzumab.
METHODS: The mechanism of action of CT-P6 and trastuzumab, both as monotherapy and in combination with paclitaxel or pertuzumab, was compared in HER2-overexpressing breast cancer and gastric cancer cell models.
RESULTS: We confirmed that CT-P6 functions in a manner similar to trastuzumab by binding to the HER2 receptor, which is central to the effects of trastuzumab in all indications.
CONCLUSIONS: Collectively, the results of this study show that the mechanisms of action of CT-P6 and trastuzumab are similar in HER2-positive breast cancer and gastric cancer models and, therefore, CT-P6 can be expected to perform similarly in the clinical setting.

PMID: 30541352 [PubMed - as supplied by publisher]

from A via a.sfakia on Inoreader https://ift.tt/2QxcdiZ